WEDNESDAY,
Feb. 24, 2016 (HealthDay News) -- Two experimental Ebola vaccines showed
promise in a clinical trial, researchers report.The vaccines triggered an
immune response and were well-tolerated among people in the phase 2 trial
conducted in Liberia, one of the West African nations hit hard by the 2014
Ebola outbreak.The trial was sponsored by the U.S. National
Institute of Allergy and Infectious Diseases.Researchers had planned to continue testing
the vaccines in a broader phase 3 trial with 28,000 people, but that was
abandoned because the decline in new Ebola cases
made the larger study impossible.
The phase 2 trial tested the cAd3-EBOZ vaccine,
which uses a chimpanzee-derived cold virus to deliver Ebola virus genetic
material. The trial also tested the rVSV-ZEBOV vaccine, which uses the
vesicular stomatitis virus -- related to the rabies virus -- to carry Ebola
genetic material.The trial included 1,500 people aged 18 and
older with no reported history of Ebola disease, and was conducted in early
2015. Participants, divided into groups of 500 people, received either one of
the two vaccines or a saline injection.
One month after getting the vaccines,
measurable Ebola antibodies were detected in 87 percent of the people who
received the cAd3-EBOZ vaccine and in 94 percent of the 500 people who received
the rVSV-ZEBOV vaccine, the researchers said.The
findings were presented Tuesday by co-principal investigator Fatorma Bolay,
director of the Liberian Institute for Biomedical Research, at the Conference
on Retroviruses and Opportunistic
Infections in Boston.
0 comments:
Post a Comment
Please insert your comments here